Search results
Results from the WOW.Com Content Network
Meropenem, sold under the brand name Merrem among others, is an intravenous carbapenem antibiotic used to treat a variety of bacterial infections. [3] Some of these include meningitis, intra-abdominal infection, pneumonia, sepsis, and anthrax.
Meropenem/vaborbactam, sold under the brand name Vabomere among others, is a combination medication used to treat complicated urinary tract infections, complicated abdominal infections, and hospital-acquired pneumonia. [2] [3] [4] It contains meropenem, a beta-lactam antibiotic; and vaborbactam, a beta-lactamase inhibitor. [4]
Carbapenems are less commonly used in the treatment of community-acquired pneumonia, as community-acquired strains of the most common responsible pathogens (Streptococcus pneumoniae, Haemophilus influenazae, atypical bacteria, and Enterobactericeace) are typically susceptible to narrower spectrum and/or orally administered agents such as ...
Pneumonia: Visual disturbance, liver toxicity. [7] Spiramycin: Rovamycine: Mouth infections: Fidaxomicin: Dificid: Treatment of Clostridioides (formerly Clostridium) difficile infection. [8] May be more narrow-spectrum than vancomycin, resulting in less bowel microbiota alteration. [9] Nausea (11%), vomiting, and abdominal pain. [10]
The treatment duration is in accordance with Darwin melioidosis treatment guidelines where there is a low rate of recrudescence and relapse. [46] Meropenem is the preferred antibiotic therapy for neurological melioidosis and for those with septic shock admitted into intensive care units. Co-trimoxazole is recommended in addition to ceftazidime ...
β-Lactam antibiotics are indicated for the prevention and treatment of bacterial infections caused by susceptible organisms. At first, β-lactam antibiotics were mainly active only against gram-positive bacteria, yet the recent development of broad-spectrum β-lactam antibiotics active against various gram-negative organisms has increased their usefulness.
Several antimicrobial drugs have been tested for the effective treatment of CRE. Fosfomycin is an antimicrobial agent that acts to inhibit UDP-N-acetylglucosamine enolpyruvyl transferase (MurA) which catalyzes one of the early steps of bacterial cell wall synthesis, and is effective against gram-negative and -positive aerobic bacteria, such as CRE.
The use of a drug of last resort may be based on agreement among members of a patient's care network, including physicians and healthcare professionals across multiple specialties, or on a patient's desire to pursue a particular course of treatment and a practitioner's willingness to administer that course.